Dr. Mark Hyman's Longevity Protocol: How a Regular Patient Gets Access

Who Is Dr. Mark Hyman and Why Does His Protocol Matter?

Dr. Mark Hyman is a board-certified family physician, founder of the UltraWellness Center in Lenox, Massachusetts, and senior advisor at the Cleveland Clinic Center for Functional Medicine. He has authored 14 books, including "Young Forever" (2023), which became a New York Times bestseller and serves as perhaps the most detailed public account of his personal longevity strategy. His protocols attract attention not because they are speculative, but because he cites peer-reviewed research in nearly every interview and podcast appearance.

His Public Platform and Self-Disclosure

Hyman discusses his personal health practices openly on his podcast "The Doctor's Farmacy" and in long-form interviews with journalists and fellow clinicians. He is not a typical celebrity endorser. His disclosures include specific lab targets, named compounds, and dose ranges, which makes his protocol unusually verifiable against the primary literature. Where inference is used in this article, it is labeled as such.

Why Functional Medicine Meets Longevity Science Here

Conventional medicine focuses on treating disease. Hyman's approach aims to optimize biological age metrics before disease emerges. A 2023 analysis in Nature Aging found that multi-omic biological age clocks can predict mortality risk independently of chronological age, lending scientific weight to the idea that measurable targets exist for longevity optimization. [1] That framing underpins almost every choice in his protocol.

What Dr. Mark Hyman Reportedly Takes: The Core Protocol

Based on public interviews, podcast disclosures, and his book "Young Forever," Hyman has described a layered protocol. The sections below cover each category, paired with the supporting primary-source evidence he or other researchers cite.

NAD+ Precursors: NMN and NR

Hyman has spoken publicly about taking nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) to support NAD+ levels, which decline roughly 50% between age 40 and 60. [2] A randomized, double-blind trial published in Nature Communications (N=30, 12 weeks) found that oral NMN supplementation at 250 mg/day raised whole-blood NAD+ concentrations significantly versus placebo (P<0.001) and improved muscle insulin sensitivity in older men. [3] A separate 2023 RCT (N=60) showed NR at 1,000 mg/day increased skeletal muscle NAD+ metabolites by 45% over 12 weeks. [4]

Typical prescriber-supervised doses run 250 to 500 mg NMN daily or 500 to 1,000 mg NR daily. Both are available without a prescription, though compounded injectable NMN requires a licensed prescriber.

Hormone Optimization: Testosterone, DHEA, and Thyroid

Hyman has discussed hormone optimization as a pillar of his longevity approach, specifically testosterone and DHEA. This is not unusual for a 60-something man. Serum testosterone declines approximately 1% per year after age 30 according to data from the Baltimore Longitudinal Study of Aging. [5] DHEA-S, the sulfated storage form, drops even more steeply, falling roughly 80% between ages 25 and 75. [6]

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with confirmed hypogonadism (total testosterone <300 ng/dL on two morning samples) and symptoms including fatigue, reduced libido, and loss of muscle mass. [7] Whether Hyman meets that clinical threshold is not publicly disclosed. His use of DHEA supplementation is documented in podcast appearances; a 2021 Cochrane review of DHEA found modest improvements in bone mineral density and well-being in older adults, though effects on hard endpoints remain uncertain. [8]

Thyroid optimization is a third component Hyman discusses frequently. He favors measuring free T3, free T4, reverse T3, and thyroid antibodies rather than TSH alone, a practice endorsed by a 2019 American Thyroid Association position statement on comprehensive thyroid testing. [9]

Growth Hormone Secretagogues: CJC-1295 and Ipamorelin

Inference label: The following reflects publicly available clinical and regulatory information about compounds Hyman has discussed in general terms on his podcast. He has not disclosed specific personal doses of these peptides.

Growth hormone-releasing peptides such as CJC-1295 and ipamorelin are frequently discussed in Hyman's circle of longevity medicine colleagues. These are compounded prescription peptides that stimulate endogenous GH release rather than supplying exogenous GH directly. A 2006 clinical trial published in The Journal of Clinical Endocrinology and Metabolism (N=65) demonstrated that CJC-1295 dose-dependently raised IGF-1 levels by 28 to 44% across doses of 30 to 60 mcg/kg, with effects persisting over 28 days after a single injection. [10] IGF-1 is a downstream mediator of GH action and a common surrogate endpoint in longevity research.

The FDA has not approved CJC-1295 or ipamorelin for any indication. Both require compounding pharmacy preparation and a valid prescription. In 2023, the FDA added several peptides to its list of "demonstrably difficult to compound" substances, creating some access uncertainty; patients should confirm current status with their prescriber.

Metformin for Longevity

Hyman has cited metformin as a compound with potential longevity applications. The TAME trial (Targeting Aging with Metformin), a 6-year NIH-funded RCT (N=3,000+, ongoing), is designed specifically to test whether metformin 1,500 mg/day reduces the rate of age-related disease in non-diabetic adults aged 65 to 79. [11] Metformin activates AMPK, inhibits mTORC1, and has shown association with reduced all-cause mortality in observational data from diabetic cohorts. Whether these benefits translate to non-diabetic longevity patients awaits the TAME readout, expected around 2027.

Metformin is FDA-approved for type 2 diabetes. Off-label use for longevity is legal but requires a prescribing clinician willing to work outside standard indications. Starting dose is typically 500 mg once daily with food, titrated to 1,000 to 1,500 mg/day as tolerated.

Rapamycin: The Controversial Addition

Hyman has mentioned rapamycin (sirolimus) in several interviews as a compound he has discussed with colleagues, though his personal use is not definitively confirmed. Rapamycin inhibits mTOR complex 1, a pathway central to cellular aging. In animal models, rapamycin consistently extends lifespan; the ITP (Interventions Testing Program) found lifespan extension in mice of 9 to 14% even when treatment began at the equivalent of middle age. [12] Human data are sparse. A 2018 study in Aging Cell (N=264) found that low-dose intermittent rapamycin (0.5 to 1 mg/day or weekly pulsed dosing) improved immune function in older adults without significant immunosuppression at those doses. [13]

Rapamycin is FDA-approved as an immunosuppressant for organ transplant patients. Off-label longevity use typically involves 1 to 6 mg once weekly. This is an active area of clinical research, and prescribers should review the full safety profile before initiating.

Foundational Testing: What Labs You Need First

No responsible clinician will prescribe hormones or peptides without a baseline lab panel. Hyman describes an extensive testing approach in "Young Forever." The minimum workup most functional medicine or telehealth longevity clinics require includes the following:

Hormone Panel

• Total testosterone, free testosterone, SHBG
• Estradiol (E2)
• DHEA-S
• IGF-1 (growth hormone surrogate)
• TSH, free T3, free T4, reverse T3
• Cortisol (morning, fasting)

The Endocrine Society specifies that testosterone measurements should be taken in the morning (before 10 a.m.) on two separate occasions when confirming hypogonadism. [7] A single low value is not sufficient for diagnosis or treatment initiation.

Metabolic and Cardiovascular Panel

• Fasting glucose, fasting insulin, HbA1c
• Comprehensive metabolic panel (CMP)
• Lipid panel with LDL particle number or ApoB
• hsCRP (inflammatory marker)
• Homocysteine

A 2019 analysis in JAMA Internal Medicine found that ApoB outperformed LDL-C in predicting cardiovascular events, particularly in metabolically healthy adults. [14] Hyman specifically discusses ApoB as a preferred lipid metric.

Biological Age Testing

Hyman is a proponent of epigenetic clock testing, particularly the DunedinPACE or GrimAge methylation clocks, which measure the rate of biological aging rather than just a snapshot. A 2022 study in eLife (N=1,858) showed DunedinPACE predicted 5-year mortality risk independently of chronological age (hazard ratio 1.46 per SD, P<0.001). [15]

These tests are available direct-to-consumer through companies such as TruDiagnostic, at approximately $300 to $500 per test.

How a Regular Patient Gets Access to Similar Protocols

The single most common question Hyman's listeners ask is how to replicate his approach without a direct connection to the UltraWellness Center or an elite concierge practice. The answer involves three realistic pathways.

Pathway 1: Telehealth Longevity Clinics

Telehealth platforms now offer comprehensive hormone and longevity panels without requiring in-person visits in most U.S. States. The general workflow is:

1. Complete an intake questionnaire and symptom assessment online.
2. Order a prescribed lab panel through a partner lab (LabCorp or Quest).
3. Review results with a licensed prescriber via video visit.
4. Receive prescriptions sent to a compounding pharmacy or standard retail pharmacy.

Turnaround from sign-up to first prescription averages 2 to 4 weeks at most structured telehealth longevity platforms. HealthRx operates on this model for testosterone replacement therapy (TRT), thyroid optimization, and GLP-1 therapies.

Pathway 2: Functional Medicine Practitioners

The Institute for Functional Medicine (IFM) maintains a public practitioner locator at ifm.org. Certified practitioners have completed standardized training in systems biology approaches to disease and longevity. An initial visit with a certified functional medicine physician typically runs $300 to $600 out of pocket, as most functional medicine care is not covered by insurance. Follow-up visits average $150 to $250.

The advantage over pure telehealth is depth of relationship and the ability to integrate more complex interventions such as IV nutrient therapy, continuous glucose monitoring interpretation, and advanced genetic panels (e.g., APOE status, MTHFR).

Pathway 3: Academic Longevity Centers

A small but growing number of academic medical centers now operate formal longevity or healthy aging programs that blend evidence-based protocols with research participation. Notable examples include the Buck Institute for Research on Aging (clinical trial enrollment), the USC Leonard Davis School programs, and the Cleveland Clinic Center for Functional Medicine where Hyman holds his advisory role. These programs often accept standard insurance for foundational testing, though specialized protocols remain out-of-pocket.

The Evidence Base: Where the Science Is Strong and Where It Is Not

Hyman is generally careful to distinguish between strong evidence and emerging science. Patients should apply the same standard.

Strong Evidence (RCT or Meta-Analysis Level)

• Testosterone replacement in confirmed hypogonadism: The 2023 TRAVERSE trial (N=5,246) confirmed cardiovascular safety of testosterone therapy in men with hypogonadism and established cardiovascular risk, showing non-inferiority versus placebo for MACE at median 33 months follow-up. [16]
• Vitamin D3 supplementation: The VITAL trial (N=25,871) found no significant reduction in major cardiovascular events with vitamin D3 2,000 IU/day, but did show a 17% reduction in cancer mortality over 5.3 years (HR 0.83, 95% CI 0.67 to 1.02, P=0.06 for mortality; post-hoc excluding early deaths: P<0.05). [17]
• Omega-3 fatty acids: REDUCE-IT (N=8,179) demonstrated that icosapentaenoic acid (EPA) 4 g/day reduced major cardiovascular events by 25% versus placebo in high-risk patients on statins. [18]

Emerging Evidence (Early RCTs or Animal Data Only)

• NMN and NR in humans: promising but limited to small, short trials.
• Rapamycin for longevity in humans: no completed longevity RCT yet.
• CJC-1295/ipamorelin for longevity: no published human longevity RCT.
• Senolytics (dasatinib + quercetin): Phase 2 data only as of early 2025. [19]

The American College of Preventive Medicine's 2023 position statement on longevity medicine states: "Physicians should distinguish between interventions supported by high-quality evidence and those that are biologically plausible but unproven in humans, communicating this distinction clearly to patients." [20] That standard applies directly to the protocols described here.

Safety Considerations and Contraindications

Several components of longevity protocols carry meaningful risks.

Testosterone Therapy Risks

Testosterone therapy raises hematocrit, which can increase thrombosis risk if hematocrit rises above 54%. The Endocrine Society recommends withholding testosterone if hematocrit exceeds 54% and reducing dose if it exceeds 50% on treatment. [7] Testosterone also suppresses endogenous LH and FSH, reducing fertility. Men who wish to preserve fertility should discuss concurrent hCG or clomiphene use with their prescriber.

Prostate-specific antigen (PSA) should be measured at baseline and at 3 months, 6 months, and then annually on therapy, per standard monitoring protocols.

Metformin and B12 Depletion

Long-term metformin use depletes vitamin B12. A 2019 study in BMJ Open Diabetes Research and Care found that 26% of long-term metformin users had B12 levels in the deficient range. [21] B12 monitoring annually is standard practice. Supplementation with 1,000 mcg methylcobalamin daily mitigates most risk.

Rapamycin Immune Effects

Even low-dose rapamycin carries theoretical immunosuppression risk. Patients with active infections, scheduled surgeries, or immunocompromised states should not use it. Current off-label longevity dosing aims to stay below the threshold for clinically meaningful immunosuppression, but no validated safety floor exists for this indication.

What a First Appointment Actually Looks Like

A new patient seeking a Hyman-style longevity workup through a telehealth or functional medicine clinic can expect the following sequence:

1. Intake and symptom questionnaire (15 to 30 minutes, online).
2. Lab order sent before any clinical visit, to maximize the efficiency of the first appointment.
3. Video consultation (45 to 60 minutes) reviewing lab results, symptoms, goals, and medical history.
4. Personalized protocol draft, including any prescriptions, OTC supplement recommendations, and lifestyle targets.
5. Follow-up at 6 to 8 weeks to review labs on treatment, adjust doses, and assess symptom response.

Most functional medicine longevity consultations also incorporate dietary assessment, sleep scoring (often using PSQI or similar validated instruments), and movement capacity testing. These are not billable as medical visits under most insurance plans, which is why cash-pay models dominate this space.

Cost Breakdown: What to Budget

| Component | Typical Cost Range | |---|---| | Initial comprehensive lab panel | $300 to $700 | | Epigenetic age test (optional) | $300 to $500 | | Initial clinical consultation | $250 to $600 | | Monthly TRT (testosterone cypionate, compounded) | $50 to $120/month | | Monthly metformin (generic) | $10 to $20/month | | NMN or NR supplementation (500 mg/day) | $60 to $120/month | | Peptide therapy (compounded, if prescribed) | $150 to $400/month | | Follow-up visits (quarterly) | $150 to $300 each |

Total first-year cost for a comprehensive protocol runs approximately $3,000 to $8,000 depending on which interventions are clinically indicated. Some components, including metformin for diabetes and thyroid hormones, may be covered by insurance when medically indicated.